Intellia Therapeutics (NTLA) Announces Positive Clinical Proof-of-Concept Data for Redosing a CRISPR-Based Therapy with its Proprietary LNP-Based Delivery Platform
Go back to Intellia Therapeutics (NTLA) Announces Positive Clinical Proof-of-Concept Data for Redosing a CRISPR-Based Therapy with its Proprietary LNP-Based Delivery Platform| (NASDAQ: NTLA) | Delayed: 12.22 +0.08 (0.66%) | |||||
|---|---|---|---|---|---|---|
| Previous Close | $12.14 | 52 Week High | $30.40 | |||
| Open | $12.50 | 52 Week Low | $11.86 | |||
| Day High | $12.65 | P/E | N/A | |||
| Day Low | $12.14 | EPS | $0.00 | |||
| Volume | 3,738,384 | |||||
